Since its establishment in 2018, Bryan Bryson's lab at MIT has concentrated on understanding the mechanisms by which immune cells identify and eradicate the bacteria causing tuberculosis (TB), a disease historically responsible for millions of deaths worldwide. The lab aims to develop new measurement techniques to accelerate the creation of better vaccines, addressing limitations of the existing BCG vaccine which offers poor protection against pulmonary TB in adults.
Bryson's approach prioritizes detailed characterization of immune responses to MTB (Mycobacterium tuberculosis), with the objective that such knowledge could unlock new therapeutic targets and vaccine strategies. The work is conducted within a broader collaboration including the Ragon Institute, representing a deliberate integration of biological engineering and infectious disease expertise.
Source & further reading
Bryan Bryson: Engineering solutions to the tough problem of tuberculosis ↗Source published 2026-01-25. This report was prepared with AI assistance from the linked primary-source material. Claims and limitations should be checked against the original announcement or research.